Sydney West Translational Cancer Research Centre
Forgot Password?

NSW Early Phase Clinical Trial Alliance Annual Meeting



Garvan Institute, Sydney

Accelerating Collaboration. Recognising the potential for early phase clinical trials to drive advances in cancer care, we are arranging a national meeting to foster collaboration in the area.The speaker program includes both international and local thought leaders in drug development, biomarkers and radiopharmaceuticals.


755 Welcome A/Prof Anthony Joshua
800 Phase 1 Clinical Trials – Emerging Ethical Considerations – Prof Elizabeth Eisenhauer
900 The ups and downs of PI3K inhibitors in the clinic and lab – Are we ever going to get there? Professor Sarah Blagden
10-1030 Morning Tea
1030-1130 Ovarian cancer as a model for discoveries that will make their way to the clinic - Prof David Bowtell
1130-1230 Histomorphometrics and Radiomics in the clinic as biomarkers - Prof Anant Madabushi
1230-130 Lunch
130 Rapid Fire Showcase - Chair - Dr Amy Prawira
130-145 Rapid Fire Showcase AsiaPacific – Hong Kong (Loong)
145-2 Rapid Fire Showcase AsiaPacific – Singapore (Tan)
2-215 Rapid Fire Showcase AsiaPacific – New Zealand (Fong/ Deva)
215-230 Rapid Fire Showcase AsiaPacific – Sydney (Kuo)
230-245 Rapid Fire Showcase AsiaPacific- Hong Kong 2 (Chiu)
245-3 Rapid Fire Showcase AsiaPacific – Melbourne/ CTA (Tran)
3-315 Rapid Fire Showcase AsiaPacific – Taiwan (Lin)

315-345 Panel Discussion – Advancing Trials in the Asia-Pacific – How do we compete with USA/ Europe? Do we even care?
Discussants – Horvath, Fuller, Hausler + Rapid Fire people
345-420 Afternoon Tea
420-445 Radionucleotides in Phase 1 – Dr Peter Eu
445-515 Combinations with radionucleotides – Lessons and Future directions – A/Prof Shaneen Sandhu
515-530 Discussion

Day 2
Theme – Learning from Old things
830-915 Moving science to new targets - Prof Hansen He
915-10 What do we do for chemo protection in phase 1 designs? - ​Dr Catherine Han
10-1030 Morning Tea
1030-1115 Learning how to dose in phase 1 - Prof Steven Ackland
1115-12 Impact of Genomics on Drug Development and Radiation - Prof Felix Feng
12-1 Lunch
1-130 Pipeline Presentation - Bayer
130-2 Pipeline Presentation - Pfizer
2-230 Pipeline Presentation - Sanofi
230-3 Pipeline Presentation - BMS
3-330 Pipeline Presentation- Merck Serono
330-4 Pipeline Presentation- Novartis
4-430 Pipeline Presentation- GSK
430-5 Pipeline Presentation- Abbvie